Merck Animal Health Completes Acquisition of Elanco’s Aqua Business
July 09 2024 - 8:30AM
Business Wire
Acquisition delivers industry-leading
portfolio, scientific and research capabilities, for enhanced
customer benefits
Merck Animal Health, known as MSD Animal Health outside of the
United States and Canada, a division of Merck & Co., Inc.,
Rahway, N.J., USA (NYSE:MRK), today announced the completion of its
acquisition of the aqua business of Elanco Animal Health
Incorporated (NYSE: ELAN). The completion of this acquisition
bolsters Merck Animal Health’s position in the aqua industry with a
comprehensive approach to promote fish health, welfare and
sustainability in aquaculture, conservation, and fisheries.
“With the completion of this acquisition, we are well positioned
within the aquaculture industry with a robust and comprehensive
portfolio across warm water, cold water, vaccines, anti-parasitic
treatments, water supplements and nutrition,” said Rick DeLuca,
president, Merck Animal Health. “We are excited to welcome our new
colleagues to Merck Animal Health and we look forward to working
together, driven by our common purpose of the Science of Healthier
Animals®.”
As a result of the acquisition, Merck Animal Health now owns
innovative products such as CLYNAV®, a new generation DNA-based
vaccine that protects Atlantic salmon against pancreas disease and
IMVIXA®, an anti-parasitic sea lice treatment and water treatment
products for warm water production, complementing Merck Animal
Health’s vaccine portfolio.
The increasing use of medicines and vaccines, nutritionals and
supplements for aquatic species is driven by the growing demand for
protein and food safety, ensuring a supply of quality food and
protecting public health.
About Merck Animal Health
At Merck, known as MSD outside of the United States and Canada,
we are unified around our purpose: We use the power of leading-edge
science to save and improve lives around the world. For more than a
century, we’ve been at the forefront of research, bringing forward
medicines, vaccines and innovative health solutions for the world’s
most challenging diseases. Merck Animal Health, a division of Merck
& Co., Inc., Rahway, N.J., USA, is the global animal health
business of Merck. Through its commitment to The Science of
Healthier Animals®, Merck Animal Health offers veterinarians,
farmers, producers, pet owners and governments one of the widest
ranges of veterinary pharmaceuticals, vaccines and health
management solutions and services as well as an extensive suite of
connected technology that includes identification, traceability and
monitoring products. Merck Animal Health is dedicated to preserving
and improving the health, well-being and performance of animals and
the people who care for them. It invests extensively in dynamic and
comprehensive R&D resources and a modern, global supply chain.
Merck Animal Health is present in more than 50 countries, while its
products are available in some 150 markets. For more information,
visit www.merck-animal-health.com and connect with us on LinkedIn,
Facebook, X (formerly Twitter) and Instagram.
Forward-Looking Statement of Merck & Co., Inc., Rahway,
N.J., USA
This news release of Merck & Co., Inc., Rahway, N.J., USA
(the “company”) includes “forward-looking statements” within the
meaning of the safe harbor provisions of the U.S. Private
Securities Litigation Reform Act of 1995. These statements are
based upon the current beliefs and expectations of the company’s
management and are subject to significant risks and uncertainties.
If underlying assumptions prove inaccurate or risks or
uncertainties materialize, actual results may differ materially
from those set forth in the forward-looking statements.
Risks and uncertainties include but are not limited to, general
industry conditions and competition; general economic factors,
including interest rate and currency exchange rate fluctuations;
the impact of pharmaceutical industry regulation and health care
legislation in the United States and internationally; global trends
toward health care cost containment; technological advances, new
products and patents attained by competitors; challenges inherent
in new product development, including obtaining regulatory
approval; the company’s ability to accurately predict future market
conditions; manufacturing difficulties or delays; financial
instability of international economies and sovereign risk;
dependence on the effectiveness of the company’s patents and other
protections for innovative products; and the exposure to
litigation, including patent litigation, and/or regulatory
actions.
The company undertakes no obligation to publicly update any
forward-looking statement, whether as a result of new information,
future events or otherwise. Additional factors that could cause
results to differ materially from those described in the
forward-looking statements can be found in the company’s Annual
Report on Form 10-K for the year ended December 31, 2023 and the
company’s other filings with the Securities and Exchange Commission
(SEC) available at the SEC’s Internet site (www.sec.gov).
View source
version on businesswire.com: https://www.businesswire.com/news/home/20240702965019/en/
Media: Kim Gorode (973) 255-8904 Kim.gorode@merck.com
Michael Close (310) 617-1067 michael.l.close@merck.com
Investors: Peter Dannenbaum (732) 594-1579
Peter.dannenbaum@merck.com
Merck (NYSE:MRK)
Historical Stock Chart
From Aug 2024 to Sep 2024
Merck (NYSE:MRK)
Historical Stock Chart
From Sep 2023 to Sep 2024